Metaraminol: Difference between revisions
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
No edit summary |
||
Line 22: | Line 22: | ||
}} | }} | ||
__NOTOC__ | __NOTOC__ | ||
{{SI}} | |||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
Line 36: | Line 32: | ||
==References== | ==References== | ||
{{reflist|2}} | |||
{{Adrenergic and dopaminergic agents}} | {{Adrenergic and dopaminergic agents}} | ||
[[Category:Sympathomimetic amines]] | [[Category:Sympathomimetic amines]] | ||
[[Category:Drugs]] | [[Category:Amphetamines]] | ||
[[Category:Cardiovascular Drugs]] | |||
[[Category:Drug]] | |||
Latest revision as of 00:03, 24 July 2014
Clinical data | |
---|---|
Pregnancy category | |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | n/a |
Protein binding | ~45% |
Metabolism | Hepatic |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C9H13NO2 |
Molar mass | 167.205 g/mol |
WikiDoc Resources for Metaraminol |
Articles |
---|
Most recent articles on Metaraminol Most cited articles on Metaraminol |
Media |
Powerpoint slides on Metaraminol |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Metaraminol at Clinical Trials.gov Clinical Trials on Metaraminol at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Metaraminol
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Metaraminol Discussion groups on Metaraminol Patient Handouts on Metaraminol Directions to Hospitals Treating Metaraminol Risk calculators and risk factors for Metaraminol
|
Healthcare Provider Resources |
Causes & Risk Factors for Metaraminol |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Metaraminol (INN, trade name Aramine) is a potent sympathomimetic amine used in the prevention and treatment of hypotension, particularly as a complication of anesthesia. It is an α1-adrenergic receptor agonist with some β effect.
Metaraminol is also used in the treatment of priapism. Although not approved for this use, it appears to be effective.[1][2][3]
References
- ↑ McDonald M, Santucci R (2004). "Successful management of stuttering priapism using home self-injections of the alpha-agonist metaraminol". Int Braz J Urol. 30 (2): 121–2. PMID 15703094.
- ↑ Koga S, Shiraishi K, Saito Y (1990). "Post-traumatic priapism treated with metaraminol bitartrate: case report". J Trauma. 30 (12): 1591–3. PMID 2258979.
- ↑ Block T, Sturm W, Ernst G, Staehler G, Schmiedt E (1988). "[Metaraminol in therapy of various forms of priapism]". Urologe A. 27 (4): 225–9. PMID 3140463.
- Pages with script errors
- CS1 maint: Multiple names: authors list
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Sympathomimetic amines
- Amphetamines
- Cardiovascular Drugs
- Drug